close read more

Our Financial Results

Dominique BRISSY

Senior Executive Vice-President,
Finance & Information Systems

“We are one of the only pharmaceutical companies to reinvest an average of 25% of our turnover (excluding generics) into R&D each year. Our priority objective is to achieve a profit that allows us to maintain this level of investment which guarantees future innovation, independence and sustainability.”

Our 2018 results

Our turnover for the financial year that ended on September 30, 2018 amounted to 4.2 billion euros, distributed between 2.9 billion euros for Servier drugs and 1.3 billion euros for generic drug-related activity. It has increased by 4.5% compared with 2016/2017 (at constant exchange rates).

Our operating income has reached 307 million euros, i.e. 5.3% of our turnover.

11 countries recorded a turnover of more than 100 million euros. Turnover outside the European Union represents 48% of consolidated turnover. The main contributors outside the EU are China, Russia, Canada and Brazil.

Thanks to its sustainable presence and long-term investments, the Group is positioned as a major player in many high-potential countries. Illustrating this, China, Brazil, Turkey and the Ukraine achieved growth of at least 10% in local currencies and are in our top 20 countries in terms of turnover.

More than nine out of every 10 boxes of Servier’s original drugs treat patients outside of France.

The Group is continuing to move forward with its international development, opening a commercial subsidiary – Servier Pharmaceuticals – and the Servier BioInnovation site in the US in 2018.

The acquisition of Shire’s oncology business in August 2018 was the year’s main event and an essential step forward for Servier’s ambition. This major external growth operation represented an investment of 2.4 billion dollars, financed with equity for over 50%, alongside a loan from a pool of banks. It illustrates the implementation of the strategy mapped out by the Group, which aims to expand its geographical presence and become a major player in oncology.

These results support the rollout of our strategies, promising to make our 10-year vision a reality.